165 related articles for article (PubMed ID: 20369073)
21. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
22. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
23. [An update on antifungal susceptibility testing].
Tapia P CV
Rev Chilena Infectol; 2009 Apr; 26(2):144-50. PubMed ID: 19621145
[TBL] [Abstract][Full Text] [Related]
24. Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.
Pina-Vaz C; Rodrigues AG; Costa-de-Oliveira S; Ricardo E; Mårdh PA
J Antimicrob Chemother; 2005 Oct; 56(4):678-85. PubMed ID: 16115827
[TBL] [Abstract][Full Text] [Related]
25. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
26. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
Arredondo-García JL; Amábile-Cuevas CF;
J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
[TBL] [Abstract][Full Text] [Related]
28. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
Pfaller MA; Diekema DJ; Rex JH; Espinel-Ingroff A; Johnson EM; Andes D; Chaturvedi V; Ghannoum MA; Odds FC; Rinaldi MG; Sheehan DJ; Troke P; Walsh TJ; Warnock DW
J Clin Microbiol; 2006 Mar; 44(3):819-26. PubMed ID: 16517860
[TBL] [Abstract][Full Text] [Related]
29. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
30. Update on clinical antifungal susceptibility testing for Candida species.
Lewis RE; Klepser ME; Pfaller MA
Pharmacotherapy; 1998; 18(3):509-15. PubMed ID: 9620102
[TBL] [Abstract][Full Text] [Related]
31. Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
Cantón E; Espinel-Ingroff A; Pemán J
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):107-19. PubMed ID: 19622060
[TBL] [Abstract][Full Text] [Related]
32. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Diekema DJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Kroeger J; Jones RN; Pfaller MA
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):233-6. PubMed ID: 19070452
[TBL] [Abstract][Full Text] [Related]
33. EUCAST technical note on anidulafungin.
Arendrup MC; Rodriguez-Tudela JL; Lass-Flörl C; Cuenca-Estrella M; Donnelly JP; Hope W;
Clin Microbiol Infect; 2011 Nov; 17(11):E18-20. PubMed ID: 21923778
[TBL] [Abstract][Full Text] [Related]
34. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Pfaller MA; Diekema DJ; Colombo AL; Kibbler C; Ng KP; Gibbs DL; Newell VA
J Clin Microbiol; 2006 Oct; 44(10):3578-82. PubMed ID: 17021085
[TBL] [Abstract][Full Text] [Related]
35. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds.
Espinel-Ingroff A; Turnidge J
Rev Iberoam Micol; 2016; 33(2):63-75. PubMed ID: 27296911
[TBL] [Abstract][Full Text] [Related]
36. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.
Ostrosky-Zeichner L; Rex JH; Pfaller MA; Diekema DJ; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
Antimicrob Agents Chemother; 2008 Nov; 52(11):4175-7. PubMed ID: 18809944
[TBL] [Abstract][Full Text] [Related]
37. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
Buchta V; Vejsova M; Vale-Silva LA
Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
[TBL] [Abstract][Full Text] [Related]
38. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole.
Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW;
Clin Microbiol Infect; 2012 Jul; 18(7):E248-50. PubMed ID: 22540149
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
[TBL] [Abstract][Full Text] [Related]
40. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
Pfaller MA; Diekema DJ; Sheehan DJ
Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
